Circulating Exosomes Biomarkers for Pancreatic Cancer

At Alfa Cytology, we specialize in the preclinical development of advanced diagnostic tools for pancreatic cancer, with a focus on circulating exosomes as biomarkers. Our services are designed to identify and validate exosome-derived biomarkers that can enhance early detection and improve patient outcomes. We provide a comprehensive range of services, from exosome isolation and characterization to biomarker validation, tailored to the specific needs of researchers and pharmaceutical companies.

Overview of Exosomes in Cancer Diagnosis

Exosomes, i.e. extracellular nanovesicles with a double membrane secreted by living cells, are typically 30-150 nm in size. Exosomes carry bioactive macromolecules of proteins, nucleic acids, lipids, and metabolites. There is growing evidence that exosomes play an important role in intercellular communication by transferring biologically active donor-cell molecules to recipient cells, leading to physiological changes in the recipient and promoting tumor growth.

Fig. 1 Highlights the roles of exosomes in pancreatic cancer progression including cell proliferation, metastasis, angiogenesis, and EMT. (Ariston G, et al., 2020)

There are several reasons for exosomes to be used as potential biomarkers for diagnosis/early detection, prognosis, and monitoring of human cancer therapy.

• Exosomes are secreted by living cells and are often found in various body fluids, which facilitates the collection of exosomes and thus enables cancer diagnosis by minimal or non-invasive fluid biopsies.
• Analysis of exosomes allows earlier detection of abnormal changes in cells of origin.
• Tumor cells secrete more exosomes than normal cells, increasing the abundance of exosomes from the tumor and making the tumor information more detectable.

Our Services

At Alfa Cytology, we specialize in the identification and analysis of circulating exosomes as diagnostic biomarkers for pancreatic cancer. Our services include:

Exosome Isolation and Characterization

• We use state-of-the-art methods such as ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture to isolate high-quality exosomes from patient plasma or serum samples.
• Comprehensive characterization of exosome size, morphology, and protein markers is conducted using techniques like nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM), and western blotting.

Exosomal RNA Profiling

• We perform exosome miRNA sequencing and pancreatic cancer analysis to identify specific miRNAs associated with pancreatic cancer.
• Exosomal mRNA and long non-coding RNA (lncRNA) analysis is available to further explore the molecular cargo for potential diagnostic and prognostic markers.

Protein Biomarker Analysis

• Our advanced proteomics platform allows us to identify and quantify exosome proteins with diagnostic relevance, such as Pancreatic cancer.
• Multiplex immunoassays and mass spectrometry are employed to profile the protein content of exosomes, providing insights into tumor progression and patient stratification.

KRAS Mutation Detection

• Using digital pancreatic cancer and next-generation sequencing (NGS), we offer sensitive detection of KRAS mutations in exosome DNA.
• These methods enable the detection of low-abundance mutations, making them suitable for early diagnosis and monitoring of therapeutic responses in pancreatic cancer patients.

Bioinformatics and Data Interpretation

• Our bioinformatics team provides comprehensive analysis and interpretation of exosome data, integrating miRNA, protein, and DNA mutation profiles to generate diagnostic signatures for pancreatic cancer.
• We offer customized reports detailing the molecular characteristics of exosomes and their clinical relevance.

Why Choose Us?

Scientific Experience

Professional team of scientists and more than ten years of experience in pancreatic cancer

Customized Service

Tailored services dedicated to ensuring customer satisfaction

Data Security

Strictly keep confidential the client's project information and experimental data

Quick Reply

Our customer service representatives are available 24 hours a day from Monday to Sunday

Would you like to know more about our pancreatic cancer diagnostic development services and solutions? We look forward to hearing from you! Please feel free to contact us for general inquiries. Our professional and patient staff will contact you as soon as possible.

References

1. Ariston Gabriel, Abakundana Nsenga, et al. "The involvement of exosomes in the diagnosis and treatment of pancreatic cancer." Molecular cancer 19.1 (2020): 1-9.
2. Uddin, Md, et al. "Exosomal microRNA in pancreatic cancer diagnosis, prognosis, and treatment: from bench to bedside." Cancers 13.11 (2021): 2777.
3. Chang, Chao-Hui, and Siim Pauklin. "Extracellular vesicles in pancreatic cancer progression and therapies." Cell death & disease 12.11 (2021): 1-12.